Caterina Casari

Caterina Casari

Auto-generated profile, based on publicly available information

Caterina Casari

Université Paris-Saclay, INSERM, Hémostase inflammation thrombose HITH U1176, Le Kremlin-Bicêtre, France

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
PLP. J. Lenting
P. J. Lenting
CCC. Casari
C. Casari
OCOlivier Christophe
Olivier Christophe
CDC. V. Denis
C. V. Denis

23 February 2015 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
LSLucia Stefanini
Lucia Stefanini
DPDavid S. Paul
David S. Paul
RRRaymond F. Robledo
Raymond F. Robledo
ECE. Ricky Chan
E. Ricky Chan
TGTodd M. Getz
Todd M. Getz
WBWolfgang Bergmeier
Wolfgang Bergmeier
The small GTPase RAP1 is critical for platelet activation and thrombus formation. RAP1 activity in platelets is controlled by the GEF CalDAG-GEFI and an unknown regulator that operates downstream of the adenosine diphosphate (ADP) receptor, P2Y12, a target of antithrombotic therapy. Here, we provide evidence that the GAP, RASA3, inhibits platelet activation and provides a link between P2Y12 and activation of the RAP1 signaling pathway. In mice, reduced expression of RASA3 led to premature platelet activation and markedly reduced the life span of circulating platelets. The increased platelet turnover and the resulting thrombocytopenia were reversed by concomitant deletion of the gene encoding CalDAG-GEFI. Rasa3 mutant platelets were hyperresponsive to agonist stimulation, both in vitro and in vivo. Moreover, activation of Rasa3 mutant platelets occurred independently of ADP feedback signaling and was insensitive to inhibitors of P2Y12 or PI3 kinase. Together, our results indicate that RASA3 ensures that circulating platelets remain quiescent by restraining CalDAG-GEFI/RAP1 signaling and suggest that P2Y12 signaling is required to inhibit RASA3 and enable sustained RAP1-dependent platelet activation and thrombus formation at sites of vascular injury. These findings provide insight into the antithrombotic effect of P2Y12 inhibitors and may lead to improved diagnosis and treatment of platelet-related disorders.

1 March 2012 in Blood
Verified
Journal Article
Closed access
PDF file
GRGhasem Rastegarlari
Ghasem Rastegarlari
JPJulie N. Pegon
Julie N. Pegon
CCCaterina Casari
Caterina Casari
SOSoline Odouard
Soline Odouard
ANAna-Maria Navarrete
Ana-Maria Navarrete
PLPeter J. Lenting
Peter J. Lenting
The relationship between low-density lipoprotein receptor–related protein-1 (LRP1) and von Willebrand factor (VWF) has remained elusive for years. Indeed, despite a reported absence of interaction between both proteins, liver-specific deletion of LRP1 results in increased VWF levels. To investigate this discrepancy, we used mice with a macrophage-specific deficiency of LRP1 (macLRP1−) because we previously found that macrophages dominate VWF clearance. Basal VWF levels were increased in macLRP1− mice compared with control mice (1.6 ± 0.4 vs 1.0 ± 0.4 U/mL). Clearance experiments revealed that half-life of human VWF was significantly increased in macLRP1− mice. Ubiquitous blocking of LRP1 or additional lipoprotein receptors by overexpressing receptor-associated protein in macLRP1− mice did not result in further rise of VWF levels (0.1 ± 0.2 U/mL), in contrast to macLRP1+ mice (rise in VWF, 0.8 ± 0.4 U/mL). This points to macLRP1 being the only lipoprotein receptor regulating VWF levels. When testing the mechanism(s) involved, we observed that VWF-coated beads adhered efficiently to LRP1 but only when exposed to shear forces exceeding 2.5 dyne/cm2, implying the existence of shear stress-dependent interactions. Furthermore, a mechanism involving β2-integrins that binds both VWF and LRP1 also is implicated because inhibition of β2-integrins led to increased VWF levels in control (rise, 0.19 ± 0.16 U/mL) but not in macLRP1− mice (0.08 ± 0.15 U/mL).

24 June 2012 in Haematologica
Verified
Journal Article
Closed access
PDF file
JPJ. N. Pegon
J. N. Pegon
MKM. Kurdi
M. Kurdi
CCC. Casari
C. Casari
SOS. Odouard
S. Odouard
CDC. V. Denis
C. V. Denis
PLP. J. Lenting
P. J. Lenting
Background Factor VIII (FVIII) and von Willebrand factor (VWF) circulate in plasma in a tight non-covalent complex, being critical to hemostasis. Although structurally unrelated, both share the presence of sialylated glycan-structures, making them potential ligands for sialic-acid-binding-immunoglobulin-like-lectins (Siglecs). Design and Methods We explored the potential interaction between FVIII/VWF and Siglec-5, a receptor expressed in macrophages using various experimental approaches, including binding experiments with purified proteins and cell-binding studies with Siglec-5 expressing cells. Finally, Siglec-5 was overexpressed in mice via hydrodynamic gene transfer. Results In different systems using purified proteins, saturable, dose-dependent and reversible interactions between a soluble Siglec-5 fragment and both hemostatic proteins were found. Sialidase treatment of VWF resulted in a complete lack of Siglec-5 binding. In contrast, sialidase treatment left interactions between FVIII and Siglec-5 unaffected. FVIII and VWF also bound to cellsurface exposed Siglec-5, as was visualized by classical immunostaining as well as by Duolinkproximity ligation assays. Co-localization of FVIII and VWF with early endosomal markers further suggested that binding to Siglec-5 is followed by endocytosis of the proteins. Finally, overexpression of human Siglec-5 in murine hepatocytes following hydrodynamic gene transfer resulted in a significant decrease in plasma levels of FVIII and VWF in these mice. Conclusions Our data indicate that FVIII and VWF may act as a ligand for Siglec-5, and that Siglec-5 may contribute to the regulation of plasma levels of the FVIII/VWF complex.

17 October 2013 in Blood
Verified
Journal Article
Closed access
PDF file
CCCaterina Casari
Caterina Casari
VDVivian Du
Vivian Du
YWYa-Ping Wu
Ya-Ping Wu
AKAlexandre Kauskot
Alexandre Kauskot
PGPhilip G. de Groot
Philip G. de Groot
PLPeter J. Lenting
Peter J. Lenting
Key Points: Adsorption of VWF type 2B mutants to platelets induces thrombocytopenia in VWD type 2B mice. VWF/platelet complexes are phagocytosed by macrophages in liver and spleen.

30 June 2013 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
CCC. Casari
C. Casari
PLP. J. Lenting
P. J. Lenting
NWN. Wohner
N. Wohner
OCOlivier Christophe
Olivier Christophe
CDC. V. Denis
C. V. Denis
Quantitative deficiencies in von Willebrand factor (VWF) are associated with abnormal hemostasis that can manifest in bleeding or thrombotic complications. Consequently, many studies have endeavored to elucidate the mechanisms underlying the regulation of VWF plasma levels. This review focuses on the role of VWF clearance pathways. A summary of recent developments are provided, including results from genetic studies, the relationship between glycosylation and VWF clearance, the contribution of increased VWF clearance to the pathogenesis of von Willebrand disease and the identification of VWF clearance receptors. These different studies converge in their conclusion that VWF clearance is a complex phenomenon that involves multiple mechanisms. Deciphering how such different mechanisms coordinate their role in this process is but one of the remaining challenges. Nevertheless, a better insight into the complex clearance pathways of VWF may help us to better understand the clinical implications of aberrant clearance in the pathogenesis of von Willebrand disease and perhaps other disorders as well as aid in developing alternative therapeutic approaches.